Published by
@ShahidNShah
@ShahidNShah
2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience is sheduled on 22-24 October 2024 in Boston, MA.With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation.The 2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience forum unites biomarker discovery scientists, imaging experts, neuroscience clinical program leads, and regulatory leaders to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.
[Read on fluid-imaging-biomarkers-neuro.com](https://fluid-imaging-biomarkers-neuro.com/take-part/register/)
Continue reading at fluid-imaging-biomarkers-neuro.com
October 23 to October 28, 2024
ADNEC (Abu Dhabi National Exhibition Centre), Al Khaleej Al Arabi Street, Abu Dhabi, Abu Dhabi, United Arab Emirates
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Media LLC. All Rights Reserved.
Built on Sep 6, 2024 at 12:08pm